Please use this identifier to cite or link to this item: https://doi.org/10.1212/01.wnl.0000313933.17796.f6
Title: No advantage of Aβ 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
Authors: Szekely, C.A.
Green, R.C.
Breitner, J.C.S.
Østbye, T. 
Beiser, A.S.
Corrada, M.M.
Dodge, H.H.
Ganguli, M.
Kawas, C.H.
Kuller, L.H.
Psaty, B.M.
Resnick, S.M.
Wolf, P.A.
Zonderman, A.B.
Welsh-Bohmer, K.A.
Zandi, P.P.
Issue Date: 10-Jun-2008
Citation: Szekely, C.A., Green, R.C., Breitner, J.C.S., Østbye, T., Beiser, A.S., Corrada, M.M., Dodge, H.H., Ganguli, M., Kawas, C.H., Kuller, L.H., Psaty, B.M., Resnick, S.M., Wolf, P.A., Zonderman, A.B., Welsh-Bohmer, K.A., Zandi, P.P. (2008-06-10). No advantage of Aβ 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70 (24) : 2291-2298. ScholarBank@NUS Repository. https://doi.org/10.1212/01.wnl.0000313933.17796.f6
Abstract: Introduction: Observational studies show reduced incidence of Alzheimer dementia (AD) in users of nonsteroidal anti-inflammatory drugs (NSAIDs). One hypothesis holds that the subset of NSAIDs known as selective Aβ 42-lowering agents (SALAs) is responsible for this apparent reduction in AD risk. Methods: We pooled individual-level data from six prospective studies to obtain a sufficient sample to examine AD risk in users of SALA vs non-SALA NSAIDs. Results: Of 13,499 initially dementia-free participants (70,863 person-years), 820 developed ncident AD. Users of NSAIDs (29.6%) showed reduced risk of AD (adjusted hazard ratio [aHR] 0.77, 95% CI 0.65-0.91). The point estimates were similar for SALAs (aHR 0.87, CI 0.72-1.04) and non-SALAs (aHR 0.75, CI 0.56-1.01). Because 573 NSAID users (14.5%) reported taking both a SALA and non-SALA, we examined their use alone and in combination. Resulting aHRs were 0.82 (CI 0.67-0.99) for SALA only, 0.60 (CI 0.40-0.90) for non-SALA only, and 0.87 (CI 0.57-1.33) for both NSAIDs (Wald test for differences, p = 0.32). The 40.7% of participants who used aspirin also showed reduced risk of AD, even when they used no other NSAIDs (aHR 0.78, CI 0.66-0.92). By contrast, there was no association with use of acetaminophen (aHR 0.93, CI 0.76-1.13). Conclusions: In this pooled dataset, nonsteroidal anti-inflammatory drug (NSAID) use reduced the risk of Alzheimer dementia (AD). However, there was no apparent advantage in AD risk reduction for the subset of NSAIDs shown to selectively lower Aβ 42, suggesting that all conventiona NSAIDs including aspirin have a similar protective effect in humans. Copyright © by AAN Enterprises, Inc.
Source Title: Neurology
URI: http://scholarbank.nus.edu.sg/handle/10635/110192
ISSN: 00283878
DOI: 10.1212/01.wnl.0000313933.17796.f6
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

101
checked on Nov 22, 2022

WEB OF SCIENCETM
Citations

100
checked on Nov 15, 2022

Page view(s)

152
checked on Nov 24, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.